Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Shanwu Ke, Yanqin Pan, Yaoyao Jin, Jiahao Meng, Yongyue Xiao, Siqi Chen, Zihao Zhang, Ruiqi Li, Fangjiu Tong, Bei Jiang, Zhitang Song, Min Zhu, Cong Ye
Benefiting from the brain-inspired event-driven feature and asynchronous sparse coding approach, spiking neural networks (SNNs) are becoming a potentially energy-efficient replacement for conventional artificial neural networks. However, neuromorphic devices used to construct SNNs persistently result in considerable energy consumption owing to the absence of sufficient biological parallels. Drawing inspiration from the transport nature of Na+ and K+ in synapses, here, a Li-based memristor (Li x AlO y ) was proposed to emulate the biological synapse, leveraging the similarity of Li as a homologous main group element to Na and K...
March 5, 2024: ACS Applied Materials & Interfaces
#22
JOURNAL ARTICLE
Nahal Abbasi, Yasaman Mirabzadeh, Golnaz Khesali, Zahra Ebrahimkhani, Hanie Karimi, Salar Vaseghi
BACKGROUND: Rapid-eye movement (REM) sleep deprivation (SD) can induce manic-like behaviors in rodents. On the other hand, lithium, as one of the oldest drugs used in neuropsychiatric disorders, is still one of the best drugs for the treatment and control of bipolar disorder. In this study, we aimed to investigate the role of chronic short-term REM SD in the induction of manic-like behaviors in female rats. METHODS: The rats were exposed to REM SD for 14 days (6 hours/day)...
March 2, 2024: Psychopharmacology
#23
JOURNAL ARTICLE
David Stacey, Beben Benyamin, S Hong Lee, Elina Hyppönen
BACKGROUND: Bipolar disorder (BPD) is a debilitating mood disorder with an unclear aetiology. A better understanding of the underlying pathophysiological mechanisms will help to identify novel targets for improved treatment options and prevention strategies. In this metabolome-wide Mendelian randomization study, we screened for metabolites that may have a causal role in BPD. METHODS: We tested a total of 913 circulating metabolite exposures assessed in 14,296 Europeans using a mass spectrometry-based platform...
February 22, 2024: Biological Psychiatry
#24
JOURNAL ARTICLE
Ahmed O Abdelaty, Engy K Tharwat, Alaa I Abdelrahman, Ayatallah Elgohary, Hebatallah Elsaeed, Amena S El-Feky, Yasmina M Ebrahim, Abdelaziz Habib, Hasnaa Abd El Latif, Yasser A Khadrawy, Heba S Aboul Ezz, Neveen A Noor, Heba M Fahmy, Faten F Mohammed, Nasr M Radwan, Nawal A Ahmed
RATIONALE: Depression is the most prevalent psychiatric disorder worldwide. Although numerous antidepressant treatments are available, there is a serious clinical concern due to their severe side effects and the fact that some depressed patients are resistant to them. Lithium is the drug of choice for bipolar depression and has been used as adjunct therapy with other groups of antidepressants. OBJECTIVES: The present study aims to investigate the effect of lithium augmentation with cerebrolysin on the neurochemical, behavioral and histopathological alterations induced in the reserpine model of depression...
February 17, 2024: Journal of Psychiatric Research
#25
JOURNAL ARTICLE
Hernán F Guillen-Burgos, Juan F Gálvez-Flórez, Sergio Moreno-Lopez, Angela T H Kwan, Roger S McIntyre
There is limited real-world evidence that evaluates the impact of monotherapy vs. combination therapy as a maintenance treatment in comorbid post-traumatic stress disorder (PTSD) in bipolar disorder (BD). Our aim was to compare lithium vs. lithium plus quetiapine in maintenance treatment in a sample of comorbid BD with PTSD. An exploratory, comparative pilot study over a 28-week period in 34 comorbid BD with PTSD patients was performed to compare monotherapy (n = 18) vs. combination therapy (n = 16) during maintenance treatment...
February 22, 2024: International Clinical Psychopharmacology
#26
JOURNAL ARTICLE
Lars Vedel Kessing, Simon Christoffer Ziersen, Frederik Mølkjaer Andersen, Thomas Gerds, Esben Budtz-Jørgensen
BACKGROUND: Long-term studies comparing nonresponse to antidepressants for major depressive disorder (MDD) are lacking. AIMS: To present systematic population-based nation-wide register data on comparative 2-year non-response within six antidepressant drug classes and 17 different antidepressants in patients with MDD. METHOD: The study included all 106,920 patients in Denmark with a first main index diagnosis of MDD at a psychiatric hospital inpatient or outpatient contact and who subsequently had a purchase of an antidepressant in the period from 1995 to 2018...
February 20, 2024: Acta Psychiatrica Scandinavica
#27
JOURNAL ARTICLE
Delfina Janiri, Alessio Simonetti, Lorenzo Moccia, Daniele Hirsch, Silvia Montanari, Marianna Mazza, Marco Di Nicola, Georgios D Kotzalidis, Gabriele Sani
(1) Background: Bipolar disorder (BD) is divided into type I (BD-I) and type II (BD-II). Polarity at onset (PO) is a proposal to specify the clinical course of BD, based on the type of the first episode at disorder onset-depressive (D-PO) or manic (M-PO). At the same time, affective temperaments represent preexisting variants of the spectrum of affective disorders. Our objectives were to investigate the hypothesis that temperament may exert an influence on PO, and that this factor can serve as an indicator of the forthcoming course of the disorder, carrying significant therapeutic implications...
December 23, 2023: Brain Sciences
#28
JOURNAL ARTICLE
Yao Kang Shuy, Sanjana Santharan, Qian Hui Chew, Shih-Ku Lin, Wen-Chen Ouyang, Chih-Ken Chen, Seon-Cheol Park, Ok-Jin Jang, Jun Hyuk Park, Kok-Yoon Chee, Kwong Sen Ding, Jamaline Chong, Ling Zhang, Keqing Li, Xiaomin Zhu, Chonnakarn Jatchavala, Pornjira Pariwatcharakul, Roy A Kallivayalil, Sandeep Grover, Ajit Avasthi, Moin Ansari, Margarita M Maramis, Paing Phyo Aung, Chay Hoon Tan, Yu-Tao Xiang, Mian-Yoon Chong, Yong Chon Park, Takahiro A Kato, Naotaka Shinfuku, Ross J Baldessarini, Kang Sim
BACKGROUND: As clinical practices with lithium salts for patients diagnosed with bipolar disorder (BD) are poorly documented in Asia, we studied the prevalence and clinical correlates of lithium use there to support international comparisons. METHODS: We conducted a cross-sectional study of use and dosing of lithium salts for BD patients across 13 Asian sites and evaluated bivariate relationships of lithium treatment with clinical correlates followed by multivariate logistic regression modeling...
March 2024: Journal of Clinical Psychopharmacology
#29
JOURNAL ARTICLE
Alessandro Miola, Mark A Frye, Leonardo Tondo, Ross J Baldessarini
BACKGROUND: Rapid cycling (RC) at least 4 recurrent episodes per year in bipolar disorder (BD) has been recognized since the 1970s. We now comment on our recent review of the topic and extensive RC analysis in a large clinical cohort, emphasizing therapeutics research. COMMENTS: Prevalence of RC-BD averages 36% for any year versus 22% in the preceding year. Rapid cycling is not a consistent feature over many years, although average long-term, annual recurrence rates are greater in RC-BD patients...
March 2024: Journal of Clinical Psychopharmacology
#30
JOURNAL ARTICLE
Andre F Carvalho, Chih-Wei Hsu, Eduard Vieta, Marco Solmi, Wolfgang Marx, Michael Berk, Chih-Sung Liang, Ping-Tao Tseng, Liang-Jen Wang
INTRODUCTION: This study aimed to estimate all-cause mortality in patients after a first-episode mania (FEM) and examine whether six guideline-recommended medications can reduce mortality. METHODS: The cohort included population-based FEM samples and matched controls from Taiwan, spanning 2007 to 2018. The primary outcomes assessed were all-cause/suicide-related mortality, while the secondary outcome focused on mortality associated with pharmacological treatments...
2024: Psychotherapy and Psychosomatics
#31
REVIEW
Yulu Meng, Shuangshuang Liu, Miao Yu, Hongyue Liang, Yu Tong, Ji Song, Jian Shi, Wen Cai, Qiong Wu, Zhifeng Wen, Jialu Wang, Feng Guo
Micronutrient deficiencies and excesses are closely related to developing and treating depression. Traditional and effective antidepressants include tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and lithium. There is no consensus on the fluctuation of zinc (Zn2+ ), magnesium (Mg2+ ), calcium (Ca2+ ), copper (Cu2+ ), iron (Fe2+ ), and manganese (Mn2+ ) ion levels in depressed individuals before and after therapy. In order to determine whether there were changes in blood and cerebrospinal fluid (CSF) levels of these ions in depressed patients compared with healthy controls and depressed patients treated with TCAs, SSRIs, or lithium, we applied a systematic review and meta-analysis...
January 8, 2024: Molecular Neurobiology
#32
REVIEW
Julia Christl, Tillmann Supprian
BACKGROUND: Lithium is considered the gold standard for the treatment of bipolar affective disorder for the prevention of recurrence of manic and depressive episodes and for augmentation treatment in unipolar severe depressive episodes. The indications for treatment with lithium do not differ for older or younger patients. Nevertheless, there are a number of aspects to be considered with respect to drug safety in the group of old patients. OBJECTIVE: The aim was to give an overview of the current literature on lithium treatment in old age and from this to derive recommendations for action...
January 2024: Der Nervenarzt
#33
REVIEW
Giulio Longo, Angelica Cicolini, Laura Orsolini, Umberto Volpe
Lumateperone (also known as ITI-007 or ITI-722) represents a novel second-generation medication characterized by a favorable safety and tolerability profile. This is attributed to its notable selectivity for D2 receptors within specific regions of the brain. The U.S. Food and Drug Administration (FDA) granted approval for the treatment of schizophrenia in adults in December 2019. Additionally, it gained approval for addressing depressive episodes associated with bipolar I and II disorders in adults, either as a standalone therapy or in conjunction with lithium or valproate, in December 2021...
November 26, 2023: Brain Sciences
#34
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
December 11, 2023: Medical Letter on Drugs and Therapeutics
#35
JOURNAL ARTICLE
Kenneth S Kendler, Henrik Ohlsson, Jan Sundquist, Kristina Sundquist
Using Swedish registers, we examine whether the prescription of and the response to antidepressants (AD), mood stabilizers (MS), and antipsychotics (AP) in the treatment of, respectively, major depression (MD), bipolar disorder (BD), and schizophrenia (SZ), are influenced by familial-genetic risk. We examined individuals born in Sweden 1960-1995 with a first diagnosis of MD (n = 257,177), BD (n = 23,032), and SZ (n = 4248) from 2006 to 2018. Drug classes and Defined Daily Dose (DDD) were obtained from the Pharmacy register using the Anatomical Therapeutic Chemical system...
December 20, 2023: Molecular Psychiatry
#36
JOURNAL ARTICLE
Paul Kriner, Emanuel Severus, Julie Korbmacher, Lisa Mußmann, Florian Seemueller
OBJECTIVES: Lithium (Li) remains one of the most valuable treatment options for mood disorders. However, current knowledge about prescription practices in Germany is limited. The objective of this study is to estimate the prevalence of current Li use over time and in selected diagnoses, highlighting clinically relevant aspects such as prescription rates in elderly patients, concomitant medications, important drug-drug interactions, and serious adverse events. METHODS: We conducted a descriptive analysis of Li prescriptions, analyzing data from the ongoing Bavarian multicenter drug safety project Pharmaco-Epidemiology and Vigilance (Pharmako-EpiVig) from the years 2014-2021...
December 19, 2023: International Journal of Bipolar Disorders
#37
Marisol Herrera-Rivero, Mazda Adli, Kazufumi Akiyama, Nirmala Akula, Azmeraw T Amare, Raffaella Ardau, Bárbara Arias, Jean-Michel Aubry, Lena Backlund, Frank Bellivier, Antonio Benabarre, Susanne Bengesser, Abesh Kumar Bhattacharjee, Joanna M Biernacka, Armin Birner, Micah Cearns, Pablo Cervantes, Hsi-Chung Chen, Caterina Chillotti, Sven Cichon, Scott R Clark, Francesc Colom, Cristiana Cruceanu, Piotr M Czerski, Nina Dalkner, Franziska Degenhardt, Maria Del Zompo, J Raymond DePaulo, Bruno Etain, Peter Falkai, Ewa Ferensztajn-Rochowiak, Andreas J Forstner, Josef Frank, Louise Frisén, Mark A Frye, Janice M Fullerton, Carla Gallo, Sébastien Gard, Julie S Garnham, Fernando S Goes, Maria Grigoroiu-Serbanescu, Paul Grof, Ryota Hashimoto, Roland Hasler, Joanna Hauser, Urs Heilbronner, Stefan Herms, Per Hoffmann, Liping Hou, Yi-Hsiang Hsu, Stéphane Jamain, Esther Jiménez, Jean-Pierre Kahn, Layla Kassem, Tadafumi Kato, John Kelsoe, Sarah Kittel-Schneider, Po-Hsiu Kuo, Ichiro Kusumi, Barbara König, Gonzalo Laje, Mikael Landén, Catharina Lavebratt, Marion Leboyer, Susan G Leckband, Mario Maj, Mirko Manchia, Cynthia Marie-Claire, Lina Martinsson, Michael J McCarthy, Susan L McElroy, Vincent Millischer, Marina Mitjans, Francis M Mondimore, Palmiero Monteleone, Caroline M Nievergelt, Tomas Novák, Markus M Nöthen, Claire O'Donovan, Norio Ozaki, Sergi Papiol, Andrea Pfennig, Claudia Pisanu, James B Potash, Andreas Reif, Eva Reininghaus, Hélène Richard-Lepouriel, Gloria Roberts, Guy A Rouleau, Janusz K Rybakowski, Martin Schalling, Peter R Schofield, Klaus Oliver Schubert, Eva C Schulte, Barbara W Schweizer, Giovanni Severino, Tatyana Shekhtman, Paul D Shilling, Katzutaka Shimoda, Christian Simhandl, Claire M Slaney, Alessio Squassina, Thomas Stamm, Pavla Stopkova, Fabian Streit, Fasil Tekola-Ayele, Anbupalam Thalamuthu, Alfonso Tortorella, Gustavo Turecki, Julia Veeh, Eduard Vieta, Biju Viswanath, Stephanie H Witt, Peter P Zandi, Martin Alda, Michael Bauer, Francis J McMahon, Philip B Mitchell, Marcella Rietschel, Thomas G Schulze, Bernhard T Baune
Background: Lithium (Li) remains the treatment of choice for bipolar disorders (BP). Its mood-stabilizing effects help reduce the long-term burden of mania, depression and suicide risk in patients with BP. It also has been shown to have beneficial effects on disease-associated conditions, including sleep and cardiovascular disorders. However, the individual responses to Li treatment vary within and between diagnostic subtypes of BP (e.g. BP-I and BP-II) according to the clinical presentation. Moreover, long-term Li treatment has been linked to adverse side-effects that are a cause of concern and non-adherence, including the risk of developing chronic medical conditions such as thyroid and renal disease...
December 2, 2023: Research Square
#38
REVIEW
Florian Buchmayer, Siegfried Kasper
Intranasal esketamine for treatment-resistant depression has been introduced and approved by the FDA and EMA in 2019 and 2020, respectively. Since then, the administration practices were found different among countries. Major depression has a high impact on many humans lives worldwide and more than a third of treated people are not responding after several treatment attempts. Additional administration with esketamine closed this gap for more than the half of these non-responders. Guidelines for the treatment of major depression recommend starting with add-on esketamine after 2-4 serious attempts of treatment with standard antidepressants (SSRI/SNRI) irrespective of augmentation with others, e...
2023: Frontiers in Psychiatry
#39
JOURNAL ARTICLE
Sijie Yu, Yuhan Zhang, Chongkai Shen, Fei Shao
OBJECTIVE: The main purpose was to evaluate the efficacy and tolerability of different medications used to treat bulimia nervosa (BN). METHODS: Randomized controlled trials (RCTs) were identified from published sources through searches in PubMed, Cochrane Library, Web of Science, and Embase from inception to November 2022. Primary outcomes were changes in the frequency of binge eating episodes and vomiting episodes from baseline to endpoint. Secondary outcomes were differences in the improvement of scores in depressive symptoms, tolerability (dropout due to adverse events) and weight change...
December 2, 2023: BMC Pharmacology & Toxicology
#40
JOURNAL ARTICLE
Giuseppe Maina, Marina Adami, Giuseppe Ascione, Emi Bondi, Domenico De Berardis, Dario Delmonte, Silvia Maffezzoli, Giovanni Martinotti, Alessandra Nivoli, Elena Ottavianelli, Andrea Fagiolini
BACKGROUND: Treatment-resistant depression (TRD) is defined by the European Medicines Agency as a lack of clinically meaningful improvement after treatment, with at least two different antidepressants. Individual, familiar, and socio-economic burden of TRD is huge. Given the lack of clear guidelines, the large variability of TRD approaches across different countries and the availability of new medications to meet the need of effective and rapid acting therapeutic strategies, it is important to understand the consensus regarding the clinical characteristics and treatment pathways of patients with TRD in Italian routine clinical practice, particularly in view of the recent availability of esketamine nasal spray...
November 23, 2023: Annals of General Psychiatry
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
